Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AXIS antimicrobial effects on tacrolimus and mycophenolate pharmacokinetics in kidney transplant recipients
2026-527106-20-00Phase 4Authorised
- Sponsor
- Oslo University Hospital
- Start
- Sep 2026
- Modality
- RNA-Targeting Small Molecules → Nucleic Acid-Directed Small Molecules → Small Molecules, Small Molecules, Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of tacrolimus, mycophenolate mofetil, ciprofloxacin, meropenem and trimethoprim + sulfamethoxazole in kidney transplant, sponsored by Oslo University Hospital. Primary endpoints: Tacrolimus exposure ratio with versus without antimicrobial treatment and Mycophenolic acid exposure ratio with versus without antimicrobial treatment. Planned start Sep 2026; status: authorised.
02
Drugs
tacrolimusmycophenolate mofetilciprofloxacinmeropenemtrimethoprim + sulfamethoxazole
03
Conditions
kidney transplant
Beyond the preview
Go deeper on 2026-527106-20-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2026-527106-20-00.